Venous thromboembolism in colorectal cancer patients with central venous catheters for 5-FU infusion-based pharmacokinetic modulating chemotherapy

Yoshikawa, Reigetsu; Yanagi, Hidenori; Noda, Masafumi; Ikeuchi, Hiroki; Nakano, Hiroki; Gega, Makoto; Tsukamoto, Kiyoshi; Oshima, Tsutomu; Inoue, Takashi; Fujiwara, Yoshinori; Shoji, Yasutsugu; Sakaki, T; Higasa, Satoshi; Hashimoto-Tamaoki, Tomoko; Yamamura, Takehira

doi:10.3892/or.13.4.627

Cited by 6 publications

(8 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Indeed, Blackwell et al (12) showed that maximum D-dimer levels since baseline occurred at the time of disease progression in 51 of 61 patients (84%) and concluded that D-dimer levels were good predictors of disease progression in patients with metastatic CRC. Yoshikawa et al (10) showed that 7.0 mg/ml, which is a much higher cut-off level than that in the current study, might be a D-dimer cut-off value for ruling out VTE in curatively resected CRC patients treated with classical FU-based chemotherapy without bevacizumab in the adjuvant setting. The normal upper limit of the D-dimer reagent used in their study was 1.2 mg/ml, which is higher than that in the current study.…”

contrasting

confidence: 52%

“…Third, central venous catheter itself could cause central venous catheter-related activation of coagulation cascade. More than 80% of indwelling central venous Jpn J Clin Oncol 2010;40 (10) catheters were associated with measurable thrombin activity at the time of removal (11), and most of the VTE in the current study was identified in the subclavian vein or superior vena cava. These data might indicate that central venous catheter itself might contribute to the VTE formation in patients treated with chemotherapy including bevacizumab.…”

Section: Discussionmentioning

confidence: 50%

“…It was reported so far that the D-dimer level was elevated in patients with CRC (8,9). Yoshikawa et al (10) reported that 7.0 mg/ml was the D-dimer cut-off value for ruling out VTE in CRC patients treated with classical FU-based chemotherapy in an adjuvant setting. However, no previous report has identified the D-dimer level that might indicate an increased risk of VTE in metastatic CRC patients treated with bevacizumab in combination with intravenous FU-based standard chemotherapy.…”

Section: Introductionmentioning

confidence: 98%

See 2 more Smart Citations

Therapeutic Significance of a D-dimer Cut-off Level of >3 g/ml in Colorectal Cancer Patients Treated with Standard Chemotherapy plus Bevacizumab

Mochizuki

Yoshino

Kojima

et al. 2010

Japanese Journal of Clinical Oncology

View full text Add to dashboard Cite

show abstract

contrasting

confidence: 52%

Section: Discussionmentioning

confidence: 50%

Section: Introductionmentioning

confidence: 98%

See 1 more Smart Citation

Therapeutic Significance of a D-dimer Cut-off Level of >3 g/ml in Colorectal Cancer Patients Treated with Standard Chemotherapy plus Bevacizumab

Mochizuki

Yoshino

Kojima

et al. 2010

Japanese Journal of Clinical Oncology

View full text Add to dashboard Cite

show abstract

“…Gemcitabine has also been associated with remarkable thrombotic and vascular side effects [ 14 ]. Lastly, venous thromboembolic disease and catheter-related thrombosis have been documented in patients receiving 5-fluorouracil [ 15 - 18 ]. The use of concomitant steroids, erythropoietin preparations and granulocyte colony-stimulating factors (G-CSF) has also been associated with an increased incidence of TEs in cancer patients [ 9 ].…”

Section: Introductionmentioning

confidence: 99%

Chemotherapy-associated thromboembolic risk in cancer outpatients and effect of nadroparin thromboprophylaxis: results of a retrospective analysis of the PROTECHT study

et al. 2011

View full text Add to dashboard Cite

BackgroundCancer patients receiving chemotherapy are at increased risk of thrombosis. Nadroparin has been demonstrated to reduce the incidence of venous and arterial thrombotic events (TEs) by about 50% in cancer outpatients receiving chemotherapy. The aims of this retrospective analysis were to evaluate the thromboembolic risk and the benefit of thromboprophylaxis according to type of chemotherapy.MethodsCancer outpatients were randomly assigned to receive subcutaneous injections of nadroparin or placebo. The incidence of symptomatic TEs was assessed according to the type of chemotherapy. Results were reported as risk ratios with associated 95% CI and two-tailed probability values.Results769 and 381 patients have been evaluated in the nadroparin and placebo group, respectively. In the absence of thromboprophylaxis, the highest rate of TEs was found in patients receiving gemcitabine- (8.1%) or cisplatin-based chemotherapy (7.0%). The combination of gemcitabine and cisplatin or carboplatin increased the risk to 10.2%. Thromboprophylaxis reduced TE risk by 68% in patients receiving gemcitabine; with a further decrease to 78% in those receiving a combination of gemcitabine and platinum.ConclusionsThis retrospective analysis confirms that patients undergoing chemotherapy including gemcitabine, platinum analogues or their combination are at higher risk of TEs. Our results also suggest that outpatients receiving chemotherapy regimens including these agents might achieve an increased benefit from thromboprophylaxis with nadroparin. Clinical Trial registration number: NCT 00951574

show abstract

“…[ 19 ] Gemcitabine and 5-fluorouracil are other drugs with remarkable thrombotic and vascular side effects. [ 20 – 24 ]…”

Section: Introductionmentioning

confidence: 99%

Incidence of venous thromboembolism following the neoadjuvant chemotherapy regimen for epithelial type of ovarian cancer

et al. 2017

View full text Add to dashboard Cite

This study aims to analyze the risk of venous thromboembolism (VTE) in patients receiving neoadjuvant chemotherapy (NACT) for epithelial ovarian cancer (EOC).A retrospective audit was conducted examining 147 patients treated for EOC. Surgical treatment with curative intent, with or without NACT and adjuvant chemotherapy, is the treatment approach, which was modified according to the patient's condition. The incidence of VTE with the most commonly used chemotherapy regimen, carboplatin, cisplatin, paclitaxel, docetaxel, and others were evaluated.This study found a 13.6% incidence of VTE in patients undergoing therapy with curative intent for EOC. No association was seen between NACT and VTE compared to VTE after standard treatment: 2/16 (12.5%) vs 5/131 (3.8%) (P = .16). Univariate and multivariate analyses also demonstrated that NACT has no risk for VTE with odds ratio (OR) = 0.89 (95% CI = 0.18–4.28) and P = 1. Results did not vary significantly with the type of chemotherapy used. Furthermore, increased incidence of VTE as an incidental finding supports the well-established role of malignancy in VTE occurrence. Univariate and multivariate analyses demonstrated that VTE occurred more frequently in menopausal women than nonmenopausal women (17.9% vs 5.8%) with OR = 3.55 (95% CI = 0.99–12.78) and P = .04 in patients aged ≥60 (19.3% vs 10%) with OR = 2.15 (95% CI = 0.83–5.57) and P = .13 but is not statistically significant.We conclude that NACT has no association with VTE and the currently used common chemotherapeutic drug combinations for ovarian cancer carry the minimal risk of thromboembolic events.

show abstract

Venous thromboembolism in colorectal cancer patients with central venous catheters for 5-FU infusion-based pharmacokinetic modulating chemotherapy

Cited by 6 publications

References 0 publications

Therapeutic Significance of a D-dimer Cut-off Level of >3 g/ml in Colorectal Cancer Patients Treated with Standard Chemotherapy plus Bevacizumab

Therapeutic Significance of a D-dimer Cut-off Level of >3 g/ml in Colorectal Cancer Patients Treated with Standard Chemotherapy plus Bevacizumab

Chemotherapy-associated thromboembolic risk in cancer outpatients and effect of nadroparin thromboprophylaxis: results of a retrospective analysis of the PROTECHT study

Incidence of venous thromboembolism following the neoadjuvant chemotherapy regimen for epithelial type of ovarian cancer

Contact Info

Product

Resources

About